Biomarkers in Kidney Cancer

A symposium presenting current state of the art and new directions for clinical and basic research

To be presented before KCRS in Boston, July 13, 2023

6:30–7:30am – Registration & Breakfast

7:30–10:30am – Symposium

BIOMARKER NEEDS AND OPPORTUNITIES IN KIDNEY CANCER RESEARCH

Kidney cancer remains one of the top 10 most common cancers in the U.S. Approximately $9.7 billion is spent annually on kidney cancer care. Although it is a relatively common malignancy, kidney cancer is a highly variable disease with unpredictable response to the available treatment regimes. There is a critical need for progress in biomarkers for kidney cancer treatment to enter into the era of personalized predictive tools. There are currently no biomarkers for guiding treatment selection in kidney cancer.

Identifying the most promising research to move emerging biomarker technologies into trials and clinical use is a driving force behind the decision to add a separate biomarker session to KCRS23. The location of this year’s KCRS23 meeting, near both the kidney cancer SPORE Dana-Farber Cancer Institute (DFCI) in Boston and the biotechnology industry hub in Cambridge, makes this the ideal time and place to devote a separate symposium to the vitally important topic. This session will attract industry partners and attendees from multiple disciplines focused on developing kidney cancer biomarkers.

Session 1

Biomarker Technologies in RCC

In this session, we explore projects at the preclinical stage of research with promise for future deployment in biomarkers for kidney cancer.

MODERATORS

TONI CHOUEIRI

Dana-Farber Cancer Institute

Mahrukh Huseni

Genentech

SPEAKERS

ARI HAKIMI

Memorial Sloan Kettering Cancer Center

Genomic DNA/RNA Biomarkers

Sabina Signoretti

Dana-Farber Cancer Institute

Spatial Biomarkers: Tissue-Based in situ Analyses including IF for Biomarker Development

David Braun

Yale Cancer Center

High-Dimensional/Spatial Tools for Biomarker Discovery in RCC

TIM SHOWALTER

Artera

How Can AI Guide Biomarker Development and Progress in RCC

HEATHER JACENE

Dana-Farber Cancer Institute

Developing Metabolic Imaging Agents in Kidney Cancer

HEDYEH EBRAHIMI

City of Hope Comprehensive Cancer Center

CT-Based Radiomics Model for the Prediction of Genomic Alterations in Renal Cell Carcinoma (RCC)

RENEE MARIA SALIBY

Dana-Farber Cancer Institute

Circulating and Intratumoral Immune Determinants of Response to Atezolizumab Plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma

discussion

Developing and Implementing New Technologies in Biomarker Research

Session 2

Clinical Biomarkers: Trial Data and Directions

In this session, we focus on biomarker data gleaned from recent clinical trials, describing both the methodology and results. The session closes with a discussion on integrating biomarker research into clinical trials, data sharing, specimen repositories, and other approaches to accelerate progress in this phase of biomarker development.